Leukemia, B-Cell: Clinical Trials

3 withdrawn. 3 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	3	Withdrawn 3

Follow Leukemia, B-Cell: new trials by email Literature Review of Leukemia, B-Cell trials Research Report on Leukemia, B-Cell

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies Liso-cel, Idelalisib, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell	Phase 3	Withdrawn	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company		2024-01-16	2024-04-02
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Duvelisib, Placebo, Rituximab - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma	Phase 3	Withdrawn	SecuraBio		2015-12-01	2021-03-17
Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma rituximab, fludarabine phosphate, pixantrone dimaleate - Leukemia, Lymphoma	Phase 3	Withdrawn	CTI BioPharma		2007-08-01	2020-10-19

Narrower conditions

Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Follicular (2)  ·  Leukemia (1)  ·  Lymphoma (1)  ·  Lymphoma, Non-Hodgkin (1)

Broader conditions

Chronic Disease (3)  ·  Disease Attributes (3)  ·  Hematologic Diseases (3)  ·  Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Leukemia, Lymphoid (3)  ·  Lymphatic Diseases (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Pathologic Processes (3)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Leukemia (2)

Interventions

Rituximab (3)  ·  Bendamustine Hydrochloride (2)  ·  fludarabine phosphate (2)  ·  Cyclophosphamide (1)  ·  duvelisib (1)  ·  fludarabine (1)  ·  idelalisib (1)

Sponsors

CTI BioPharma (1)  ·  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1)  ·  SecuraBio (1)

Countries

United States (3)  ·  Austria (1)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Norway (1)  ·  Spain (1)  ·  Sweden (1)  ·  United Kingdom (1)

Top investigators

Hagop Youssoufian, MD (1)  ·  Igor Gorbatchevsky, MD (1)